CompletedPhase 2NCT00417573
Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections
Studying Recurrent infections associated with rare immunoglobulin isotypes deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Center for Rheumatic Disease, Allergy, & Immunology
- Principal Investigator
- Nabih I Abdou, MD, PhDCenter for Rheumatic Disease, Allergy, Immunology
- Intervention
- IV Gamunex 10%(drug)
- Enrollment
- 10 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2004 – 2006
Study locations (1)
- Center for Rheumatic Disease, Allergy, Immunology, Kansas City, Missouri, United States
Collaborators
Grifols Therapeutics LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00417573 on ClinicalTrials.gov